Acumen Pharmaceuticals (NASDAQ: ABOS) insider files to sell shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider Daniel OConnell filed a notice of proposed sale of company common stock under Rule 144. The filing covers 5,388 shares of common stock to be sold through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/12/2026 and an aggregate market value of $9,306.56 based on the form data. These shares were acquired on 01/07/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.

The notice also lists recent sales of Acumen common stock by OConnell over the prior days in January 2026, including 4,649 shares on 01/05/2026 for gross proceeds of $9,163.33 and 37,755 shares on 01/07/2026 for gross proceeds of $74,980.95. By signing, the seller represents that they are not aware of any undisclosed material adverse information about Acumen’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5388	9306.56	60573425	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/07/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			5388	01/07/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4649	9163.33
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	5102	10031.44
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	37755	74980.95
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	8143	14815.32
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/09/2026	12941	22832.18

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Acumen Pharmaceuticals (ABOS) disclose?

It discloses that Daniel OConnell plans to sell 5,388 shares of Acumen Pharmaceuticals common stock under Rule 144 through Merrill Lynch on the NASDAQ.

How were the 5,388 Acumen Pharmaceuticals shares being sold acquired?

The 5,388 shares were acquired on 01/07/2026 via vesting of a restricted stock unit award granted as part of Acumen’s equity compensation plan.

What trading details are provided for the planned Acumen (ABOS) share sale?

The filing states the shares are common stock, to be sold through Merrill Lynch, with an approximate sale date of 01/12/2026 on the NASDAQ, and an aggregate market value of $9,306.56 as shown in the form.

What recent Acumen Pharmaceuticals share sales by Daniel OConnell are listed?

The notice lists several sales in early January 2026, including 4,649 shares on 01/05/2026 for $9,163.33 and 37,755 shares on 01/07/2026 for $74,980.95, along with additional smaller transactions on nearby dates.

What representation does the seller make in the Acumen Pharmaceuticals Form 144?

By signing, the seller represents that they do not know any material adverse information about Acumen’s current or prospective operations that has not been publicly disclosed.